These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15015892)

  • 1. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
    Rajkumar SV
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
    Barlogie B
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
    Dimopoulos MA; Anagnostopoulos A
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):8-16. PubMed ID: 15015891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.
    Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):3-7. PubMed ID: 15015890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
    Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
    Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
    Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
    Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
    Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immunomodulatory drugs in multiple myeloma.
    Anderson KC
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):23-32. PubMed ID: 15015893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
    Zervas K; Mihou D; Katodritou E; Pouli A; Mitsouli CH; Anagnostopoulos A; Delibasi S; Kyrtsonis MC; Anagnostopoulos N; Terpos E; Zikos P; Maniatis A; Dimopoulos MA;
    Ann Oncol; 2007 Aug; 18(8):1369-75. PubMed ID: 17693650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
    Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R
    J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
    Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
    Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide in the management of multiple myeloma.
    Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G
    Semin Hematol; 2001 Jul; 38(3):250-9. PubMed ID: 11486313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide in multiple myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
    Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
    Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
    Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE
    J Clin Oncol; 2002 Nov; 20(21):4319-23. PubMed ID: 12409330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide in multiple myeloma: past, present and future.
    Harousseau JL
    Future Oncol; 2006 Oct; 2(5):577-89. PubMed ID: 17026450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide treatment in multiple myeloma.
    Strasser K; Ludwig H
    Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.